Locations:
SearchAdvertisement
Offers a new option for patients 60 and older with relapsed/refractory disease
Researchers develop first-of-its-kind neoantigen atlas to better understand immunotherapy resistance
Combining dual inhibition with anti-PD1 therapy yielded >60% rate of complete tumor regression
What’s coming up at ASH and beyond
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Retrospective study evaluates clinical upstaging during neoadjuvant treatment
Retrospective study finds acceptable cancer control among most histologic subtypes with intravesical therapy
Machine learning models assess intraoperative tissue perfusion
Combining mind, body and lifestyle practices in alignment with conventional cancer treatment
Higher type 2 immunity observed in persistent CAR T cells
Pregnancy did not appear to increase the risk of recurrence in patients or complications in their children
Advertisement
Advertisement